Pfizer Fails To Make Its Mark In China-Focused Biosimilars Market
US-Based Firm Announces It Will Halt Biosimilar Development
Executive Summary
Pfizer threw in the towel for biosimilar development in China last week, just three years after opening its $350m Global Biotechnology Center, based in the Hangzhou Economic Development Area.